Soft Tissue Infections

Chapter

Abstract

Skin and soft tissue infections are a common cause of hospitalization, disability, and antibiotic therapy. Infections commonly managed by surgeons and intensivists include complicated cellulitis and abscesses, severe necrotizing soft tissue infections, and surgical site infections. This chapter will describe the epidemiology, pathogenesis, and therapeutic approach to each. Particular attention is given to necrotizing soft tissue infections and the differentiation of necrotizing infections from non-necrotizing infections, as this is a critical requirement for optimal outcome.

Keywords

Skin and soft tissue infection Necrotizing soft tissue infection Necrotizing fasciitis Necrotizing cellulitis Myositis Myonecrosis 

References

  1. 1.
    Guidance for Industry: Uncomplicated and complicated skin and skin structure infections- developing antimicrobial drugs treatment. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 1998.Google Scholar
  2. 2.
    Jones ME, Karlowsky JA, Draghi DC, et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents. 2003;22(4):406–19.PubMedGoogle Scholar
  3. 3.
    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41(10):1373–406.PubMedGoogle Scholar
  4. 4.
    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–52.PubMedGoogle Scholar
  5. 5.
    May AK, Stafford RE, Bulger EM, et al. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt). 2009;10(5):467–99.Google Scholar
  6. 6.
    May AK. Skin and soft tissue infections. Surg Clin North Am. 2009;89(2):403–20, viii.PubMedGoogle Scholar
  7. 7.
    May AK. Skin and soft tissue infections: the new surgical infection society guidelines. Surg Infect (Larchmt). 2011;12(3):179–84.Google Scholar
  8. 8.
    Sartelli M, Malangoni MA, May AK, et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg. 2014;9(1):57.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Phan HH, Cocanour CS. Necrotizing soft tissue infections in the intensive care unit. Crit Care Med. 2010;38(9 Suppl):S460–8.PubMedGoogle Scholar
  10. 10.
    Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee [see comments]. Infect Control Hosp Epidemiol. 1999;20(4):250–78.PubMedGoogle Scholar
  11. 11.
    May AK, Daniels TL, Obremskey WT, et al. Steroids in the treatment of group a streptococcal necrotizing soft tissue infection. Surg Infect (Larchmt). 2011;12(1):77–81.Google Scholar
  12. 12.
    Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis. 1995;1(3):69–78.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 2007;57(1):7–13.PubMedGoogle Scholar
  14. 14.
    Awad SS, Elhabash SI, Lee L, et al. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg. 2007;194(5):606–10.PubMedGoogle Scholar
  15. 15.
    Moran GJ, Abrahamian FM, Lovecchio F, et al. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med. 2013;44(6):e397–412.PubMedGoogle Scholar
  16. 16.
    Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis. 2005;40(4):562–73.PubMedGoogle Scholar
  17. 17.
    Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis. 2007;44(4):471–82.PubMedGoogle Scholar
  18. 18.
    Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290(22):2976–84.PubMedGoogle Scholar
  19. 19.
    Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg. 1996;224(5):672–83.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51(3):291–8.PubMedGoogle Scholar
  21. 21.
    Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436–44.PubMedGoogle Scholar
  22. 22.
    King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144(5):309–17.PubMedGoogle Scholar
  23. 23.
    Moran GJ, Amii RN, Abrahamian FM, et al. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis. 2005;11(6):928–30.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334(4):240–5.PubMedGoogle Scholar
  25. 25.
    Swartz MN. Clinical practice. Cellulitis. N Engl J Med. 2004;350(9):904–12.PubMedGoogle Scholar
  26. 26.
    Chartier C, Grosshans E. Erysipelas. Int J Dermatol. 1990;29(7):459–67.PubMedGoogle Scholar
  27. 27.
    Chartier C, Grosshans E. Erysipelas: an update. Int J Dermatol. 1996;35(11):779–81.PubMedGoogle Scholar
  28. 28.
    Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA. 1993;269(3):390–1.Google Scholar
  29. 29.
    Eriksson BK, Andersson J, Holm SE, et al. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis. 1998;27(6):1428–36.PubMedGoogle Scholar
  30. 30.
    Kiska DL, Thiede B, Caracciolo J, et al. Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis. 1997;176(4):992–1000.PubMedGoogle Scholar
  31. 31.
    Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med. 1982;97(4):493–6.PubMedGoogle Scholar
  32. 32.
    Bouma J, Dankert J. Recurrent acute leg cellulitis in patients after radical vulvectomy. Gynecol Oncol. 1988;29(1):50–7.PubMedGoogle Scholar
  33. 33.
    Dan M, Heller K, Shapira I, et al. Incidence of erysipelas following venectomy for coronary artery bypass surgery. Infection. 1987;15(2):107–8.PubMedGoogle Scholar
  34. 34.
    Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999;318(7198):1591–4.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med. 1992;93(5):543–8.PubMedGoogle Scholar
  36. 36.
    Hook III EW, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med. 1986;146(2):295–7.PubMedGoogle Scholar
  37. 37.
    Kielhofner MA, Brown B, Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med. 1988;148(11):2451–2.PubMedGoogle Scholar
  38. 38.
    Lebre C, Girard-Pipau F, Roujeau JC, et al. Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol. 1996;132(7):842–3.PubMedGoogle Scholar
  39. 39.
    Perl B, Gottehrer NP, Raveh D, et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis. 1999;29(6):1483–8.PubMedGoogle Scholar
  40. 40.
    Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med. 1990;150(9):1907–12.PubMedGoogle Scholar
  41. 41.
    Bradsher Jr RW, Snow RM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Med. 1984;77(4C):63–7.PubMedGoogle Scholar
  42. 42.
    Grayson ML, McDonald M, Gibson K, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis. 2002;34(11):1440–8.PubMedGoogle Scholar
  43. 43.
    Brogan TV, Nizet V, Waldhausen JH, et al. Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients. Pediatr Infect Dis J. 1995;14(7):588–94.PubMedGoogle Scholar
  44. 44.
    Burech DL, Koranyi KI, Haynes RE. Serious group A streptococcal diseases in children. J Pediatr. 1976;88(6):972–4.PubMedGoogle Scholar
  45. 45.
    Mascini EM, Jansze M, Schouls LM, et al. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents. 2001;18(4):395–8.PubMedGoogle Scholar
  46. 46.
    Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999;18(12):1096–100.PubMedGoogle Scholar
  47. 47.
    Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med. 1952;13(4):389–99.PubMedGoogle Scholar
  48. 48.
    Stevens DL, Gibbons AE, Bergstrom R, et al. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158(1):23–8.PubMedGoogle Scholar
  49. 49.
    Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J. 2003;96(10):968–73.PubMedGoogle Scholar
  50. 50.
    Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol. 1992;127(2):155–9.PubMedGoogle Scholar
  51. 51.
    Martin JM, Green M, Barbadora KA, et al. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med. 2002;346(16):1200–6.PubMedGoogle Scholar
  52. 52.
    York MK, Gibbs L, Perdreau-Remington F, et al. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol. 1999;37(6):1727–31.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Sriskandan S, McKee A, Hall L, et al. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother. 1997;40(2):275–7.PubMedGoogle Scholar
  54. 54.
    Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352(14):1445–53.PubMedGoogle Scholar
  55. 55.
    Broder J, Jerrard D, Olshaker J, et al. Low risk of infection in selected human bites treated without antibiotics. Am J Emerg Med. 2004;22(1):10–3.PubMedGoogle Scholar
  56. 56.
    Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites. Cochrane Database Syst Rev. 2001;(2):CD001738.Google Scholar
  57. 57.
    Zubowicz VN, Gravier M. Management of early human bites of the hand: a prospective randomized study. Plast Reconstr Surg. 1991;88(1):111–4.PubMedGoogle Scholar
  58. 58.
    Brook I, Frazier EH. Aerobic and anaerobic bacteriology of wounds and cutaneous abscesses. Arch Surg. 1990;125(11):1445–51.PubMedGoogle Scholar
  59. 59.
    Bosshardt TL, Henderson VJ, Organ Jr CH. Necrotizing soft-tissue infections. Arch Surg. 1996;131(8):846–52.PubMedGoogle Scholar
  60. 60.
    Grayson ML. Diabetic foot infections. Antimicrobial therapy. Infect Dis Clin North Am. 1995;9(1):143–61.PubMedGoogle Scholar
  61. 61.
    Itani KM, Dryden MS, Bhattacharyya H, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199(6):804–16.PubMedGoogle Scholar
  62. 62.
    Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2004;38(1):17–24.PubMedGoogle Scholar
  63. 63.
    Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2000;44(12):3408–13.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481–90.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Weigelt J, Kaafarani HM, Itani KM, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg. 2004;188(6):760–6.PubMedGoogle Scholar
  66. 66.
    Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260–6.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Stevens DL, Wallace RJ, Hamilton SM, et al. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis. 2006;42(5):729–30.PubMedGoogle Scholar
  68. 68.
    Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41 Suppl 5:S341–53.PubMedGoogle Scholar
  69. 69.
    Psoinos CM, Flahive JM, Shaw JJ, et al. Contemporary trends in necrotizing soft-tissue infections in the United States. Surgery. 2013;153(6):819–27.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis. 2011;53(2):144–9.PubMedGoogle Scholar
  71. 71.
    Anaya DA, McMahon K, Nathens AB, et al. Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg. 2005;140(2):151–7.PubMedGoogle Scholar
  72. 72.
    Childers BJ, Potyondy LD, Nachreiner R, et al. Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg. 2002;68(2):109–16.PubMedGoogle Scholar
  73. 73.
    Hsiao CT, Weng HH, Yuan YD, et al. Predictors of mortality in patients with necrotizing fasciitis. Am J Emerg Med. 2008;26(2):170–5.PubMedGoogle Scholar
  74. 74.
    Liu YM, Chi CY, Ho MW, et al. Microbiology and factors affecting mortality in necrotizing fasciitis. J Microbiol Immunol Infect. 2005;38(6):430–5.PubMedGoogle Scholar
  75. 75.
    Wong CH, Chang HC, Pasupathy S, et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003;85-A(8):1454–60.PubMedGoogle Scholar
  76. 76.
    Feingold DS, Weinberg AN. Group A streptococcal infections. An old adversary reemerging with new tricks? Arch Dermatol. 1996;132(1):67–70.PubMedGoogle Scholar
  77. 77.
    Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis. 2001;33 Suppl 2:S84–93.PubMedGoogle Scholar
  78. 78.
    Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321(1):1–7.PubMedGoogle Scholar
  79. 79.
    Stevens DL. Dilemmas in the treatment of invasive Streptococcus pyogenes infections. Clin Infect Dis. 2003;37(3):341–3.PubMedGoogle Scholar
  80. 80.
    Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect Dis. 2005;5(8):501–13.PubMedGoogle Scholar
  81. 81.
    Stevens DL, Bryant AE. Pathogenesis of Clostridium perfringens infection: mechanisms and mediators of shock. Clin Infect Dis. 1997;25 Suppl 2:S160–4.PubMedGoogle Scholar
  82. 82.
    Stevens DL, Tweten RK, Awad MM, et al. Clostridial gas gangrene: evidence that alpha and theta toxins differentially modulate the immune response and induce acute tissue necrosis. J Infect Dis. 1997;176(1):189–95.PubMedGoogle Scholar
  83. 83.
    Brett MM, Hood J, Brazier JS, et al. Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect. 2005;133(4):575–82.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Kimura AC, Higa JI, Levin RM, et al. Outbreak of necrotizing fasciitis due to Clostridium sordellii among black-tar heroin users. Clin Infect Dis. 2004;38(9):e87–91.PubMedGoogle Scholar
  85. 85.
    Chew SS, Lubowski DZ. Clostridium septicum and malignancy. ANZ J Surg. 2001;71(11):647–9.PubMedGoogle Scholar
  86. 86.
    Wong CH, Khin LW, Heng KS, et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32(7):1535–41.PubMedGoogle Scholar
  87. 87.
    Bilton BD, Zibari GB, McMillan RW, et al. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg. 1998;64(5):397–400.PubMedGoogle Scholar
  88. 88.
    McHenry CR, Piotrowski JJ, Petrinic D, et al. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg. 1995;221(5):558–63.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Chan T, Yaghoubian A, Rosing D, et al. Low sensitivity of physical examination findings in necrotizing soft tissue infection is improved with laboratory values: a prospective study. Am J Surg. 2008;196(6):926–30.PubMedGoogle Scholar
  90. 90.
    Yaghoubian A, de Virgilio C, Dauphine C, et al. Use of admission serum lactate and sodium levels to predict mortality in necrotizing soft-tissue infections. Arch Surg. 2007;142(9):840–6.PubMedGoogle Scholar
  91. 91.
    Hsiao CT, Lin LJ, Shiao CJ, et al. Hemorrhagic bullae are not only skin deep. Am J Emerg Med. 2008;26(3):316–9.PubMedGoogle Scholar
  92. 92.
    Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis. 2007;44(5):705–10.PubMedGoogle Scholar
  93. 93.
    Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med. 1984;310(26):1689–93.PubMedGoogle Scholar
  94. 94.
    Freischlag JA, Ajalat G, Busuttil RW. Treatment of necrotizing soft tissue infections. The need for a new approach. Am J Surg. 1985;149(6):751–5.PubMedGoogle Scholar
  95. 95.
    Majeski JA, Alexander JW. Early diagnosis, nutritional support, and immediate extensive debridement improve survival in necrotizing fasciitis. Am J Surg. 1983;145(6):784–7.PubMedGoogle Scholar
  96. 96.
    Rouse TM, Malangoni MA, Schulte WJ. Necrotizing fasciitis: a preventable disaster. Surgery. 1982;92(4):765–70.PubMedGoogle Scholar
  97. 97.
    Sudarsky LA, Laschinger JC, Coppa GF, et al. Improved results from a standardized approach in treating patients with necrotizing fasciitis. Ann Surg. 1987;206(5):661–5.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Wall DB, de Virgilio C, Black S, et al. Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. Am J Surg. 2000;179(1):17–21.PubMedGoogle Scholar
  99. 99.
    Green RJ, Dafoe DC, Raffin TA. Necrotizing fasciitis. Chest. 1996;110(1):219–29.PubMedGoogle Scholar
  100. 100.
    Okoye O, Talving P, Lam L, et al. Timing of redebridement after initial source control impacts survival in necrotizing soft tissue infection. Am Surg. 2013;79(10):1081–5.PubMedGoogle Scholar
  101. 101.
    Echols J, Friedman B, Mullins R, et al. Initial experience with a new system for the control and containment of fecal output for the protection of patients in a large burn center. Chest. 2004;126(4 SUPPL):862S.Google Scholar
  102. 102.
    Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg. 2000;87(6):718–28.PubMedGoogle Scholar
  103. 103.
    Cheadle WG. Risk factors for surgical site infection. Surg Infect (Larchmt). 2006;7 Suppl 1:S7–11.Google Scholar
  104. 104.
    Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013;14(1):73–156.Google Scholar
  105. 105.
    Nelson RL, Glenny AM, Song F. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev. 2009;(1):CD001181.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  1. 1.Division of Trauma and Surgical Critical Care, Department of SurgeryVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations